Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-12-08
1994-12-27
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31485
Patent
active
053766628
ABSTRACT:
The specification discloses a method of treating a human or animal patient suffering from a pain syndrome secondary to nerve injury comprising daily administration to such patient of from about 0.4 milligrams to about 2.0 milligrams of the opiate-receptor antagonist naloxone for a treatment period of from around 3 months to around 12 months, depending upon the patient's needs. Delivery is preferably at or near the nerve injury site by a number of conventional injection methods.
REFERENCES:
patent: 4105659 (1978-08-01), Archer
patent: 4582835 (1986-04-01), Lewis et al.
patent: 4668685 (1987-05-01), Shami
patent: 4673679 (1987-06-01), Aungst et al.
patent: 4722928 (1988-02-01), Boswell et al.
patent: 4753635 (1988-06-01), Sagen et al.
patent: 4760069 (1988-07-01), Rzeszotarski et al.
patent: 4769372 (1988-09-01), Kreek
patent: 4785000 (1988-11-01), Kreek et al.
patent: 4857533 (1989-08-01), Sherman et al.
patent: 4863928 (1989-09-01), Atkinson et al.
patent: 4888346 (1989-12-01), Bihari et al.
patent: 4889860 (1989-12-01), Rzeszotarski et al.
patent: 4990617 (1991-02-01), Boswell et al.
patent: 5013739 (1991-05-01), Bihari et al.
"A Randomized, Controlled Trail of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury", vol. 322, New Eng. J. Med., (May 1990), pp. 1405-1411, Bracken et al.
"Opiate-Receptor Antagonist Nalmefene Improves Neurological Recovery after Traumatic Spinal Cord Injury in Rates through a Central Mechanism", vol. 245, J. Pharmacology & Experimental Therapeutics, 742-48 (1988), Faden et al.
"111-Prostaglandin Hyperalgesia: Relevance of the Peripheral Effect for the Analgesic Action of Opioid-Antagonists", Prostaglandins, Aug. 1979, vol. 18, No. 2, pp. 201-208, Ferreira et al.
"Site of Analgesic Action of Aspirin-like Drugs and Opioids", In Mechanisms of Pain and Analgesic Compounds, New York: Raven Press pp. 309-321, Ferreira, 1979.
"Endogenous Opiates and Nociception: A Possible Functional Role in Both Pain Inhibition and Detection as Revealed by Intrathecal Naloxone", Neuroscience Letters, vol. 24 (1981) pp. 161-164, Dickenson et al.
"Effect of Naloxone Upon Diffuse Noxious Inhibitory Controls (DNIC) in the Rat", Brain Research vol. 240 (1981) 387-402, Le Bars et al.
"Reaction Thresholds to Pressure in Edematous Hindpaws of Rates and Responses to Analgesic Drugs", The Journal of Pharmacology and Experimental Therapeutics vol. 150, No. 1, pp. 165-171 Winter et al.
"Analgesia Produced by Low Doses of the Opiate Antagonist Naloxone in Arthritic Rats is Reduced in Morphine-Tolerant Animals", Brian Research, vol. 371 (1986), pp. 37-41 Kayser et al.
"Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain", Nature, vol. 278, (1979), pp. 740-741, Levine et al.
"Local Inhibition of Inflammatory Pain by Naloxone and its N-Methyl Quaternary Analogue," European Journal of Pharmacology, vol. 96, pp. 277-283, Rios et al., 1983.
"Analgesia and hyperalgesia produced in the rat by intrathecal naloxone", Brain Research, vol. 189 (1980), pp. 593-597, Woolf.
"Behavorial evidence for a bidirectional effect of systemic naloxone in a model of experimental neuropathy in the rat", Brain Research, vol. 494 (1989), pp. 276-384, Attal et al.
"Behavioural and electrophysiological studies on the paradoxial antinociceptive effects of an extremely low dose of naloxone in an animal model of acute and localized inflammation", Exp Brain Res (1988) pp. 402-410 Kayser et al.
"II-Prostaglandin Hyperalgesia: The Peripheral Analgesic Activity of Morphine, Enkephalins and Opioid Antagonists", Prostaglandins, vol. 18, pp. 191-200, Ferreira et al. 1979.
"I-Prostaglandin Hyperalgesia, A cAMP/CA.sup.2+ Dependent Process", Prostaglandins, vol. 18, No. 2 (1979), pp. 179-190, Ferreira et al.
"Drug Interaction in the Field of Analgesic Drugs", Proceedings of the Royal Society of Medicine, vol. 58, pp. 978-983, Lasagne, 1978.
"Naloxone alters pain perception and somatosensory evoked potentials in normal subjects", Nature, vol. 270 (1977), pp. 620-622, Buchsbaum et al.
"Antinociceptive Activity of Narcotic Agonist and Partial Agonist Analgesics and other Agents in the Tail-Immersion Test in Mice and Rats", Neuropharmacology, vol. 15 (1976), pp. 683-688, Sewell et al.
"Inhibition of Inflammatory Pain by Naloxone and its N Methyl Quaternary Analogue", Life Sciences, vol. 31 (1982), pp. 1209-1212, Rios et al.
"Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats", Brain Research, vol. 226 (1981) pp. 344-348, Kayser et al.
"Opioid and Nonopioid Mechanism May Contribute to Dynorphin's Pathophysiological Actions in Spinal Cord Injury", Annals of Neurology, vol. 27, No. 1 (1990), pp. 67-74, Faden.
"Dynorphin A-(1-17) Induces Alterations in Free Fatty Acids, Excitatory Amino Acids, and Motor Function Through An Opiate-Receptor-Mediated Mechanism", The Journal of Neuroscience (1990), 10(12), pp. 3793-3800, Bakshi et al.
"Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data", J. Neurosurg vol. 76 pp. 23-31 (1992), Bracken et al.
Hydorn Michael B.
Richter Johann
LandOfFree
Method of attenuating nerve injury induced pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of attenuating nerve injury induced pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of attenuating nerve injury induced pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-919953